This funding round was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis. Additional support came from existing investor Morningside, alongside new investors Tenmile, Brandon Capital, and others.
Sanofi Ventures joins investors backing Australian radionuclide company
February 6, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics emerges as Asia Pacific leader in off the shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News -
Pharmacy Guild rejects AMA alarm over broader prescribing powers
July 1, 2026 - - Latest News -
Significant day marked by negotiation trigger and wholesaler remuneration changes
July 1, 2026 - - Latest News -
Governments backs inhaled RNA therapy with the potential to change the future of chronic lung disease treatment
July 1, 2026 - -
Protection gap leaves older Australians vulnerable this winter
July 1, 2026 - - Latest News


